Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacoepidemiological Study on the Use of Arcoxia Under Actual Conditions of Use in France

Next Previous
X
Search
Trial Profile

Pharmacoepidemiological Study on the Use of Arcoxia Under Actual Conditions of Use in France

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoricoxib (Primary) ; Celecoxib
  • Indications Acute pain; Ankylosing spondylitis; Back pain; Cervicobrachial syndrome; Dental pain; Dysmenorrhoea; Gout; Juvenile rheumatoid arthritis; Musculoskeletal pain; Osteoarthritis; Periarthritis; Rheumatic disorders; Tendinitis
  • Focus Therapeutic Use
  • Sponsors Organon

    • Most Recent Events

    • 15 Apr 2016 Primary endpoints and treatment table amended.
    • 26 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top